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New therapeutic strategies developed recently for chronic lymphocytic leukemia (CLL) have led to remarkable treatment response
rates and complete hematological remissions. This means highly sensitive and speciﬁc techniques are increasingly needed to
evaluate minimal residual disease (MRD) in CLL patients. Quantitative MRD levels can be used as prognostic markers, where
total MRD eradication is associated with prolonged survival. Nowadays, PCR and ﬂow cytometry techniques used to detect
MRD in CLL patients can generate reliable and quantitative results with the highest sensitivity. MRD Flow is based on four-color
ﬂow cytometry using speciﬁc antibody combinations. For allele speciﬁc oligonucleotide real-time quantiﬁcation (ASO RQ) PCR
individual primers are designed to detect a speciﬁc immunoglobulin heavy chain (IgH) rearrangement in each patient clone. Five
comprehensive studies investigated and compared the sensitivity and speciﬁcity of both methods. Groups of patients receiving
diﬀerent therapies were analyzed at diﬀerent time points to generate quantitative MRD levels and MRD kinetics. All studies
conﬁrmedthatbothmethodsgenerateequivalentresultswithregardtosensitivityandMRDquantiﬁcation,althougheachmethod
has advantages and disadvantages in the daily routine of a standard hematological laboratory. Here, we review these investigations
and compare their results in the light of modern therapies.
1.Background
Minimal residual disease (MRD) is deﬁned by persistence of
very low levels of residual malignant cells in posttreatment
cancer patients. These cells can only be detected by the most
sensitive techniques available [1].
Formerly, reduction in tumor burden and clinical symp-
toms were the treatment goals in chronic lymphocytic
leukemia (CLL) [2]. Although conventional therapies result
in overall response rates of 40 to 60% [3, 4], only 4% of
patients achieve complete remission (CR) [5]. Even the use
of purine analogues such as ﬂudarabine leads to CR, nodular
CR, or partial remission in only less than half of the patients
[5,6].Thefrequentpersistenceofasigniﬁcanttumorburden
after therapy is the reason why detecting MRD in CLL was
previously not considered clinically important in most cases
[1, 7].
Recently, however, the application of new therapies such
as allogeneic or autologous stem cell transplantation (SCT),
or monoclonal antibodies, has resulted in a signiﬁcant
proportion of patients attaining more profound remissions
[7]. CR as deﬁned by the National Cancer Institute spon-
sored working group (NCI/IWCLL) guidelines is mainly
characterizedbytheabsenceoftumorandclinicalsymptoms
such as lymphadenopathy, hepatomegaly, or splenomegaly,
incombinationwiththeabsenceofmorphologicalCLLsigns
and stability of other parameters in peripheral blood [8, 9].
However, patients who achieved complete remission on the
basis of these criteria without any morphological evidence
often still have considerable inﬁltration of malignant cells in
the bone marrow, and this can only be detected by sensitive
methods [1].
Two methods are currently available for detecting MRD
in CLL: multiparameter ﬂow cytometric (MFC) analyses and
polymerase chain reaction-based techniques (PCR). These
methods are able to detect one malignant cell in 10,000–
100,000 normal leukocytes [9, 10]. MRD detection has been
used for years as a prognostic marker in other hematological2 Advances in Hematology
disorders such as acute lymphoblastic leukemia and chronic
myeloid leukemia [11, 12]. In contrast, the exact relevance
of MRD detection in CLL remains to be elucidated. Several
studies investigated the correlation between MRD levels and
clinical outcome in CLL, providing evidence that eradication
of residual disease levels can serve as a marker for prolonged
survival and a better outcome [7, 13, 14].
For a long time it was not clear whether the application
of highly sensitive MRD detection methods is capable of
providing a more accurate prediction of a patient’s outcome
thantheNCIcriteria.Thus,Rawstronetal.[7]comparedthe
event-free (EFS) and overall survival (OS) rates of patients
with CR according to the NCI criteria after treatment with
alemtuzumab and/or autologous SCT. In this study, patients
were deﬁned as MRD negative if CLL cells comprised less
than0.05%ofallbonemarrowleukocytesthreemonthsafter
therapy. The authors found that approximately a quarter
of patients achieving complete remission according to the
NCI criteria were detected as MRD positive by MFC assays.
In parallel, patients who were classiﬁed as MRD positive
by highly sensitive assays had signiﬁcantly higher risks of
relapse and also exhibited a shorter OS, independently of
CR as deﬁned by NCI criteria [7, 14]. High MRD levels
also correlated with more rapid clinical progression and
shortersurvivalthanforpatientswithlowerMRDlevels[14].
However, it must be noted that patients achieving an MRD-
negative status cannot be considered cured, since most of
thesepatientsdevelopprogressivediseaseafteragivenperiod
of time [7].
There is evidence that not only the individual MRD
level provides prognostic information but also MRD kinetics
[15]. In a previous study, 32 CLL patients were analyzed
for their MRD level dynamics after stem cell transplan-
tation. Although there were intraindividual diﬀerences,
patients could be divided into ﬁve groups showing that
MRD response within 12 months after transplantation is
a strong indicator for durable remission and long-term
MRD-negative survival [15]. In addition, quantitative MRD
assessments during or after therapy are increasingly used to
evaluate the response and adapt the duration of diﬀerent
types of therapeutic approaches [15, 16].
2.MRD DetectionMethods andPrinciples
In contrast to other hematological malignancies, CLL is not
linked to a speciﬁc structural chromosomal abnormality that
could be used for MRD detection. However, in common
with other B cell malignancies, it is possible to identify the
malignant clone using IgH gene rearrangements or a speciﬁc
cell surface antigen combination [1]. Therefore, cytogenetic
methods cannot be used to detect MRD in CLL, but rather
molecular or genetic assays such as PCR or ﬂow cytometry.
2.1. Flow Cytometry Analyses. Flow cytometry is based on
identifying cells by their cell surface antigen expression
usingﬂuorescence-labeledantibodiesthatbindtothesurface
antigens. Cells pass through laser beams where they refract
the light. After antigen-antibody binding, the ﬂuorochromes
emit ﬂuorescence light. The refracted light is analyzed
by forward (FSC) and sideways scatter (SSC) to identify
intracellular organization of granularity (SSC) and the cell’s
volume (FSC) [17]. Today, ﬂow cytometers with two or
more lasers are available, allowing the use of additional
ﬂuorochromes. Diﬀerent antigen combinations measured by
multiple ﬂuorochromes are characteristic for each group
of cells and vary during diﬀerentiation, migration, and
proliferation.
For ﬂow cytometry analyses, it is critical to identify
and distinguish CLL cells from other peripheral blood
mononuclear cells (PBMCs), especially healthy B and T cells.
Therefore, diﬀerent clusters of diﬀerentiation (CD) patterns
are analyzed by immunophenotyping [17].
CLL cells typically express CD19, CD20, and CD23 in
combination with the T cell marker CD5 in the absence of
other T cells markers (Figure 1)[ 8]. Compared to healthy
B cells, the expression of CD20 and CD79b is lower on
CLL cells [18]. CD23 is an important marker for separating
CLL from other non-Hodgkin lymphomas, such as the
mantel cell lymphoma where CD5 and other B cell surface
antigens are also expressed, but generally not CD23 [8]. The
presence or absence of CD38 on the cell surface is used as a
prognostic marker but varies between patients [19]. CD43 is
homogeneously expressed on CLL cells, but also on mantel
cell, Burkett’s, and some follicular lymphomas [20]. Each
CLL clone is also restricted in expression of kappa or lambda
immunoglobulin light chains [21].
B cell expression patterns diﬀer substantially during
maturation.MarkerssuchasCD10,CD20,CD21,CD23,and
CD37, as well as various expression levels of Ig chains can
be used to identify the diﬀerent maturation stages of B cells
in peripheral blood and bone marrow [17]. CD19, CD22,
and CD72 are pan-B cell markers that are expressed on both
immature and mature B cells. CD19 is a potent marker for
B cell detection in peripheral blood because it is expressed
on virtually all B cells. The presence of CD79 molecules,
for example, CD79a and CD79b, is only found in B-lineage
cellsbutvariesgreatlyduringmaturationanddiﬀerentiation.
Cytoplasmatic CD79a is one of the earliest B cell markers.
In more mature B cells both CD79 chains are expressed in
combination with surface membrane bound Ig (sIg) as an
sIg-CD79 complex [17].
Diﬀerent antibody combinations have been tested
to distinguish between CLL and healthy B cells. CD19/
CD5/CD20/CD79b as well as CD81/CD22/CD19/CD5 were
shown to be suitable for identifying CLL cells in peripheral
blood [22, 23].
In bone marrow samples, CLL and B cells are more
diﬃcult to identify due to changes in antigen expression
during diﬀerentiation. Rawstron et al. [7] achieved the
best results using three diﬀerent antibody combinations:
CD19/CD5/CD38/CD79 plus CD19/CD5/CD20/CD79b and
CD19/CD5/CD38/CD20.
Sensitivity and speciﬁcity also depend on the minimum
number of cells required to identify a cell population as
being CLL cells in ﬂow cytometric analyses. Contamination
rates or the number of cells acquired in a sample can be
limiting factors for detection [10]. The absolute number ofAdvances in Hematology 3
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cells required to characterize a cell population is deﬁned as
the absolute speciﬁcity threshold [24].
2.2. Polymerase Chain Reaction (PCR). Real-time quantita-
tive PCR (RQ-PCR) is used to generate quantitative MRD
results. The principle of this PCR is an indicator that
generatesadetectableﬂuorescencesignalduringoraftereach
PCR cycle, thus providing quantitative results directly after
measurement [25]. Three types of ﬂuorescence formats are
available: DNA intercalating ﬂuorochromes, hydrolysis, or
hybridization probe techniques [25]. The principle for all of
these techniques is the increase in ﬂuorescence during the
exponential extension/elongation of the DNA product.
Intercalating dyes are mainly used for nonspeciﬁc detec-
tion. The dye binds to double-stranded DNA, which leads
to an increase in ﬂuorescence during the elongation period.
Since new DNA strands are generated exponentially, the dye
can bind more substrate [25]. Hydrolysis and hybridization
p r o b et e c h n i q u e sc a nb eu s e df o rs p e c i ﬁ cP C Rp r o d u c t
detection.
Hydrolysis probes use the activity of the Thermus aquati-
cus (Taq) polymerase to detect and quantify a speciﬁc PCR
product. When the hydrolysis probe is conjugated with a
reporter and a quencher ﬂuorochrome is located within the
target sequence, as long as the DNA strand is intact, the
quencher ﬂuorochrome absorbs the reporter ﬂuorochrome
due to their close contact. During the elongation step,
the hydrolysis probe is replaced by Taq-polymerase and
hydrolyzed. As a consequence, both ﬂuorochromes loose
their proximity, the reporter ﬂuorochrome is no longer
quenched and becomes detectable [25]. Again the detectable
ﬂuorochrome increases exponentially in every PCR cycle.
Hybridization probes work with a donor and acceptor
ﬂuorochrome. During the annealing phase and the early
elongation step, both ﬂuorochromes are in contact and one
can detect emission from the donor ﬂuorochrome [25].
To detect MRD, it is necessary to identify DNA sequences
that are unique to CLL cells. Such a PCR target can
be the immunoglobulin gene (Ig), for example, Ig heavy
chain, Ig kappa, or Ig lambda. During antigen-independent4 Advances in Hematology
maturation in the bone marrow, the antibody variability
increases due to rearrangement of germline variable (V),
diversity (D) and joining (J) gene segments of the Ig [26].
This allows a speciﬁc VDJ “ﬁngerprinting” combination for
each immature (pre-) lymphocyte [25]. Therefore, in princi-
ple, all malignant cells in one patient exhibit the same clonal
origin with identically rearranged Ig genes. Identifying the
patient-speciﬁcIgarrangementisthebasisfordevelopingthe
PCRtechnique,whichcanthengenerateverysensitiveresults
using speciﬁc primers for each patient clone. A problem
associated with using speciﬁc immunoglobulin genes can
be somatic hypermutations that change the primer binding
region after the lymphocytes contact antigens. Fortunately,
although somatic hypermutations are high in myeloma
( m e d i a n8 % ) ,t h e ya r el o wi nc o m m o nC L L( 2 % )[ 27].
Gene rearrangement often leads to diﬀerentiation into
subclones, for example, secondary Ig gene rearrangements,
ongoing VH to DH-JH joining or VH replacement, which
can occur during the time between diagnosis and relapse.
Mostly, the D-J junctional region remains unaﬀected during
the secondary rearrangements, and therefore primers are
designed around this region [25]. However, if oligoclonal
clones are found at the time of diagnosis [13], it is
unclear which clone should be monitored by PCR for early
identiﬁcation of relapse. If using only one oligonucleotide
primer, the PCR probes can loose speciﬁcity for the chosen
target region and the clone causing the relapse is possibly not
identiﬁed. This may lead to false negative results, which is a
known problem in childhood acute lymphoblastic leukemia
(ALL) [28]. Thus, if clonality is detected in a CLL patient,
two Ig PCR targets can be used to minimize false negatives.
3. Low-SensitivityMethods: Two-Color Flow
Cytometryand ConsensusPCR
3.1. CD5+/CD19+ Flow Cytometry. The ﬁrst ﬂow cytometric
analysis for detecting MRD in CLL, CD5+/CD19+ ﬂow
cytometry, was an insensitive and only qualitative technique,
since single antigens were insuﬃcient to separate CLL cells
from normal B cells [7, 29, 30]. Two-color cytometry
was used to detect the coexpression of a B cell marker
such as CD19 or CD20, and CD5 (which under normal
circumstances is only expressed on T cells) in conjunction
with monoclonality detected by surface light chain expres-
sion [1, 31]. Patients with less than 25% of CD19+CD5+
cells/total CD19+ cells in peripheral blood and <15% of
CD19+CD5+/total CD19+ c e l l si nb o n em a rr o ww e r ed e ﬁ n e d
asMRDnegative[29].UsingcoexpressionofCD20andCD5,
the cutoﬀ point was deﬁned as 10% to identify residual CLL
cells [31].
Not only is this form of assessment not quantitative,
but sensitivity is also very low and variable. For example,
samples detected as MRD negative in the two-color ﬂow
analysis might have 100-fold higher levels of disease than
MRD samples detected as MRD positive by newer and more
sensitive techniques [7]. The sensitivity of two-color ﬂow
cyometry is also limited by the presence of normal B cells
in the peripheral blood or B cell progenitor cells in the
bone marrow, especiallywhenCLL cellnumbers are verylow
[1, 7].
Two-color ﬂow cytometry usually detects one CLL cell
in 200 healthy B cells [32]. Some studies also tested the
expression of CD79b and CD20, but interpatient variation
in antigen expression means that two-color ﬂow cytometric
analyses are not informative for all patients, regardless
of the chosen antibody combination [7, 33, 34]. Another
limitation is the rate of false positive results after autologous
CD34+ sorted PB stem cell transplantation. On average,
36% of normal CD19+-B and progenitor cells also exhibit
CD5 coexpression within the ﬁrst two months, persisting
in some patients for over one year after transplantation
[35].
3.2. Consensus Primer PCR. For this technique, a standard
oligonucleotide primer set comprising two primers is used
to amplify the third complementarily region (CDRIII) of the
IgHgene.TheﬁrstprimerdetectstheconsensusJH-sequence
region, and the second one the family speciﬁc framework
region [36]. For CLL detection, framework region, one or
three are possible targets [7, 22]. Consensus PCR can be
used for qualitative MRD detection giving less prognostic
information [1] and achieves variable sensitivity of around
10−3 [7, 24], with sensitivity limited by the presence of
normal leukocytes [1]. Rawstron et al. found that consensus
PCR detects CLL cells when they represented at least 2% of
all B cells; otherwise the primer also binds to the germline
DNA of other healthy cells [7]. Other limitations are B cells
with a polyclonal background [24, 36]. The detection rate of
consensus PCR also depends on the framework or JH region
used [37].
CLL patients can be divided into mutated or unmutated
IgH subgroups [38], and since mutations can abrogate
binding of the consensus primers, MRD detection with
standard consensus PCR was only possible in approximately
70%–80% of all patients [7]. To increase the sensitivity
and speciﬁcity of PCR detection, speciﬁc primer sets were
developed by the European BIOMED-2 collaborative study
group. These primers increased sensitivity of PCR detection
in non-Hodgkin lymphomas to 82%–100% and potentially
the majority of CLL. [39] In a comparative analysis by
B¨ ottcher et al. [24] on patients who had received allogeneic
or autologous SCT, consensus PCR was compared to MRD
Flow using ASO RQ-PCR as a reference method. Consensus
PCR was shown to be inferior to both the other techniques
with respect to quantiﬁcation and sensitivity [24]. Using
consensus PCR, the authors achieved sensitivity ranging
from 2.2 × 10
−4 for patients with a monoclonal CLL
background and up to 5.2 × 10
−3 for a polyclonal CLL
background. Nevertheless, this was superior to the studies
from Rawstron et al. [7], probably due to reductions in
healthyBcellsafterSCTenhancingspeciﬁcity.Thelimitation
of a polyclonal B cell background was also shown in other
studies [36]. Due to the drawbacks of consensus PCR for
MRD detection and the development of more eﬃcient
treatments, other quantitative PCR techniques such as ASO
RQ-PCR, and more sensitive ﬂow cytometric analysis have
now replaced consensus PCR in MRD diagnostics [7, 24].Advances in Hematology 5
4.High-SensitivityMethods: Multiparameter
Flow Cytometry (MFC)andASOIGHPCR
4.1. Multiparameter Flow Cytometry. Further therapeutic
developments and the idea of using MRD as a prognostic
marker made it necessary to ﬁnd methods that are not
only more sensitive but also quantitative [22]. One of the
major problems of the commonly used CD19+/CD5+ ﬂow
cytometry analyses was that one could only analyze the
expression of two antigens. This proved not enough to
reliably identify CLL cells nor achieve good separation of
healthy B cells and CLL cells due to their overlapping antigen
pattern.
The advantages of multicolor ﬂow cytometry are that
it can diﬀerentiate between cell groups by using a greater
number of antibodies, measure large numbers of cells, and
identify very small cell populations, all important to reach
higherspeciﬁcity.Itcanalsobeusedforperipheralbloodand
bone marrow analyses [7].
In 2001, Rawstron et al. [7]a n a l y z e dd i ﬀerent ﬂow
cytometry approaches based on investigating the variable
antigenwithadvancedtechniques.Usingbloodfrompatients
posttreatment with alemtuzumab and/or autologous stem
cell transplantation, the authors compared conventional
four-color ﬂow cytometry, which detected the cell surface
combination CD19/CD5/λ/κ, with MRD Flow employing a
specially developed antibody combination and gating strat-
egy. Kolmogorov-Smirnov calculations were used to identify
the extent of separation of each antibody combination tested
[7]. The MRD Flow antibody combination achieving the
highest sensitivity of all tested antibody combinations was
CD19/CD5/CD20/CD79b for peripheral blood.
To deﬁne the speciﬁcity and sensitivity of the MRD
Flow, the authors designed dilution series where CLL cells
were mixed with healthy leukocytes in concentrations from
1:1 to 1:16,384 [7]. These dilutions were also used for
conventional four-color ﬂow cytometry measurements and
consensus PCR performed with a JH and FR3 consensus
primer. For ﬂow cytometry experiments, a minimum of
0.5 × 106 leukocytes were incubated with diﬀerent antibody
combinations,andeachtestwasanalyzedbetween50000and
800000 cells using a Becton Dickinson FACSort instrument.
Comparing the sensitivity of both ﬂow cytometry meth-
ods in the dilution studies revealed that the MRD Flow
was 2 logs more sensitive than the conventional four-color
analyses or consensus PCR. The median was 0.005 for MRD
Flow, 0.4 for four-color ﬂow cytometry, and 0.6 for PCR [7].
The sensitivity of the two-color ﬂow cytometry was assessed
as 1.2. In addition, the speciﬁcity of the MRD Flow for
identifying CLL cells was higher than for conventional four-
color ﬂow cytometry. Whereas four-color ﬂow cytometry
could only detect an abnormal kappa-lambda ratio in CD5+
B cells when about 30% were CLL cells, the MRD Flow was
able to detect CLL cells when they only represented around
1% of all B cells.
This study used a speciﬁc gating strategy to completely
separate CLL from normal B cells or B cell progenitors. MRD
Flow was also used to monitor patients with CR according
to NCI criteria. The authors showed that the absence of
clinical symptoms was not identical to the absence of CLL
cells in peripheral blood or bone marrow. Thus, MRD Flow
analyses provided information about incomplete eradication
or relapse of CLL, allowing prognosis of event-free survival
or disease progression.
As t u d yb yB¨ ottcher et al. [22] investigated the possibility
of using MRD Flow and ASO RQ-PCR to quantify MRD lev-
els in CLL patients after treatment with immunochemother-
apy, including the CD20 monoclonal antibody rituximab.
Since rituximab has proven to be very eﬀective in CLL
treatment and therefore has become a component of current
standard therapy, it was essential to test whether all methods
used for MRD detection still work at the presence of this
antibody [40, 41].
For their study, the authors analyzed 530 samples from
63 patients enrolled in the CLL8 trial of the GCLLSG.
At diﬀerent time points, samples were tested for MRD
levels (during therapy, one and three months after ther-
apy, and in three-month intervals thereafter). All patients
included in this study were randomized and divided in two
groups, each receiving diﬀerent therapies. In the ﬁrst group,
patients underwent six courses of a chemotherapy regime
combining ﬂudarabine, cyclophosphamide, and rituximab
(FCR), whereas patients in the other group were treated
with ﬂudarabine and cyclophosphamide (FC) alone [22].
Samples were classiﬁed as MRD negative if MRD levels were
10
−4 or less, and as MRD positive when CLL cell numbers
were greater than 10
−4 [22]. Detection of MRD levels at the
threshold of 10
−4 is the given standard for MRD detection
according to the IWCLL guidelines [8].
The authors showed that MRD Flow and ASO RQ-
PCR gave concurring qualitative results in 85.3% (452
samples) of all measured samples. This included 278 samples
that were MRD positive for both methods within the
quantitative range; 34 samples that were simultaneously
positive outside the quantitative range (positive results that
cannot be precisely quantiﬁed, for example, positive PCR
samples that started with a very low template number due
to marginal CLL cells), and 140 samples that were MRD
negative. ASO RQ-PCR proved to be more sensitive for
qualitative MRD detection, identifying 72.8% (386) as MRD
positive whereas MRD Flow only detected 59.6% (316) as
MRDpositive.All316MRD-positivesamplestestedbyMRD
Flow (within and outside the quantitative range) achieved a
median MRD level of 3.3 × 10
−3. The median quantitative
range for the 386 MRD-positive ASO RQ-PCR samples was
2.2 ×10
−4.
In the 278 concurring ASO RQ-PCR/MRD Flow samples
within the quantitative range, MRD Flow reached a median
quantitative range of 8.2 × 10
−3 (range: 6.1 × 10
−5 to
9.5 × 10
−1), which correlated very well with the achieved
ASO RQ-PCR median range of 8.5×10
−3 (range: 5.0×10
−5
to 6.5 × 100).
Discordant results were achieved in 14.7% (78) of sam-
ples. Most of these samples (67) were classiﬁed as outside the
quantitative range, and ASO RQ-PCR generated more pos-
itive results than MRD Flow. Quantiﬁable MRD levels were
detected in seven samples by ASO RQ-PCR but not by MRD
Flow. In these cases, insuﬃcient leucocytes were available to6 Advances in Hematology
allow detection of CLL cells by MRD Flow. Thus, the MRD
levels matched or were lower than the MRD Flow sensitivity.
In summary, MRD Flow generated equivalent quanti-
tative results compared to ASO RQ-PCR according to the
standard given by the NCI guidelines but had a lower
sensitivity for qualitative detection (78% of all samples
were ASO RQ-PCR positive but only 59.6% were MRD
Flow positive). Such information about the sensitivity and
quantiﬁcation ranges of both methods is important for
interpreting MRD data and avoiding unquantiﬁable results.
ToﬁndoutwhetherrituximabinﬂuencesMRDdetection
sensitivity, B¨ ottcher et al. correlated the results of MRD Flow
for both therapeutic arms. Diﬀerent antibody combinations
were tested, and ASO RQ-PCR was used as a reference
m e t h o ds i n c ei ti sn o ta ﬀected by treatment with antibodies
[22]. This comparison showed that (i) patients with the FCR
combination had signiﬁcant lower MRD levels detected by
MRDFlowand(ii)rituximabhadnoeﬀectonthespeciﬁcity,
sensitivity, or quantiﬁcation of MRD Flow compared to ASO
RQ-PCR [8]. Due to these ﬁndings, it was necessary to
analyze whether the antibody combinations without CD20
produced superior results; but in factantibody combinations
including CD20 were as eﬀective as combinations without
CD20. To explain their results, the authors analyzed the
kinetics of CD20 expression in CLL cells as well as benign
B cells during and after treatment with rituximab. They
concluded that during therapy the disappearance of CD20
on CLL cells coincides with a depletion of benign CD20+ B
cells, thus reducing the B cell background and inﬂuencing
the speciﬁcity of MRD Flow. Sayala et al. were more critical
onthispoint,advisingagainstusingCD20combinationsdue
to rituximab’s eﬀect on normal B cells [1].
The coexistence of many ﬂow cytometry assays such
as MRD Flow, conventional four-color, and CD19+/CD5+
ﬂ o wc y t o m e t r ym a k e si td i ﬃcult to compare factors such
as therapy response. To address this problem, Rawstron
et al. [10] developed an international standard for using
ﬂow cytometry in MRD diagnostics, to facilitate comparison
between diﬀerent ﬂow cytometry techniques as well as PCR
assays. The authors used MRD Flow as well as ASO RQ-PCR
andalsoexaminedwhichkindofpatientmaterial(peripheral
blood or bone marrow) is required for measurements during
diﬀerent times of treatment. Eradication of malignant CLL
cells from peripheral blood during therapy with monoclonal
antibodies is faster than signiﬁcant clearance in the bone
marrow. This information is important for making decisions
aboutthetimepointandmaterialusedforMRDassessments
during monitoring [1]. For example, intratherapeutic moni-
toring optimally requires bone marrow analyses.
These standards were based on examining 728 samples
of peripheral blood and bone marrow using a cutoﬀ point
of 0.01%. Similarly to other studies, the authors found well-
correlated results for MRD Flow and ASO RQ-PCR in 94.7%
of cases [7, 22]. The accuracy for MRD Flow was 95.0%,
and again ASO RQ-PCR showed higher sensitivity for MRD
detection [10].
Several antibody combinations were tested for detecting
CLL cells in peripheral blood, identifying the combinations
of CD20/CD79b/CD19/CD5, CD20/CD38/CD19/CD5 and
CD22/CD81/CD19/CD5,asthosewiththehighestsensitivity
and signiﬁcant correlation between MRD Flow and ASO
RQ-PCR. The correlation between materials depended on
the treatment type and time of assessment [10]. Discordant
results were found in samples from patients during or
shortly after treatment with alemtuzumab whereas material
from patients not receiving alemtuzumab gave concordant
results in 91.6% of samples. In some cases, peripheral
blood was shown to be equivalent or more sensitive than
bone marrow. This likely occurs mainly in the regeneration
phase when increasing proliferation of normal progenitor
cells in the bone marrow leads to a higher background of
cells. Nevertheless, bone marrow analyses were necessary for
MRD detection during and within the ﬁrst three months
after therapy with alemtuzumab or rituximab [23], since
neoplastic B cells as well as normal cells can be depleted in
peripheral blood for several months after treatment but can
still persist in the bone marrow [10].
In summary, MRD Flow is capable of detecting one CLL
cell in 104 healthy leukocytes with a sensitivity as eﬀective
as ASO RQ-PCR within the given standard according to
the international consensus and IWCLL guidelines [8, 22].
This means that MRD Flow reaches the diagnostic standard.
Given antibody combinations, as well as a special gating
strategy providing detailed instructions for identifying CLL
cells [10], are necessary to separate CLL cells from healthy
cells and enhance sensitivity and speciﬁcity.
However, the technical background is important since
ﬂow cytometry analyses are inﬂuenced by several factors
that decrease sensitivity and speciﬁcity [24, 42]. Such
factors include unspeciﬁc antibody binding, which leads to
false positive results or contamination of the ﬂow system,
which leads to suboptimal detection of CLL cells. Even
diﬀerent procedures for erythrocyte lysis can inﬂuence ﬂow
cytometric analyses [24, 43, 44].
Compared to other methods, MRD Flow assessments
generate results very rapidly (Table 1). Additionally, MRD
Flow is not as expensive as the sensitive PCR methods and
is available in most hematological laboratories. Using this
sensitive ﬂow cytometry technique, it is also not necessary to
know the exact immunophenotype of the CLL patient clone.
The problem of variable antigen expression patterns between
diﬀerent patients can be reduced by using standardized
antibody combinations that are highly sensitive for most of
thevariationsalthoughpatientswithatypicalantigenproﬁles
remain a problem for ﬂow cytometry detection [7].
4.2. ASO IGH RQ-PCR. The allele speciﬁc oligonucleotide
immunoglobulin heavy chain real-time quantitative poly-
merase chain reaction (ASO IGH RQ-PCR) is an MRD
detection method based on designing individual oligonu-
cleotide primers for each patient clone. This generates high
speciﬁcity and sensitivity of up to 10
−5 [1, 24, 45]. However,
this high sensitivity depends on sequencing samples for each
patient before designing the necessary ﬂuorogenic probe.
Three diﬀerent options for designing an ASO RQ-PCR are
described [25].
The ﬁrst approach is the ASO probe, where the indi-
vidually designed probe is positioned at the tumor-speciﬁcAdvances in Hematology 7
Table 1: Overview about the most important diﬀerences between diﬀerent MRD detection methods.
MRD Flow ASO RQ-PCR
sensitivity 10−4 10−4–10−5
speciﬁcity
depends on depends on
(i) measured cell type (i) annealing temperature
(ii) B cell background (ii) length of ampliﬁed DNA
(iii) antibody quality
method
(i) surface antigen detection (i) detection of ampliﬁed DNA with individual primer
(ii) possible antibody combinations: (ii) possible targets:
(1) CD20/CD79b/CD19/CD5 (1) Ig heavy chain
(2) CD20/CD38/CD19/CD5 (2) Ig kappa
(3) CD22/CD81/CD19/CD5 (3) Ig lamda
limiting factors (i) high normal B cell background (i) somatic hypermutation (rare in CLL)
(ii) antibody quality (ii) loss of target gene
advantages
(i) high number of cells can be measured (i) highest sensitivity of all available methods
(ii) cost eﬀective (ii) low interference with normal B cells
(iii) available in day-to-day business
(iv) rapid (approx. 1 hour)
disadvantages
(i) knowlegment for reliable results (i) expensive (sequencing, PCR primers)
(ii) contamination of the system (ii) time-consuming
(iii) not available in every diagnostic laboratory
gene sequence in the CDRIII region of the IgH gene
rearrangement [22]. The forward and reverse primers are
conventional and positioned in the germline sequences
ﬂanking the tumor speciﬁc sequence. Primer competition
between the MRD target and comparable Ig rearrangements
innormalcellsmightleadtodecreasedﬂuorescenceintensity
if the number of CLL cells in the sample is very low.
The two other approaches are based on generating an
ASO forward or ASO reverse primer. The ASO forward
primer is positioned within the tumor-speciﬁc sequence in
combinationwithaconventional germlineprobeandreverse
primer. The probe is normally positioned in the J gene
segment. The increase in ﬂuorescence correlates with the
percentage of CLL cells in the sample due to the exponential
sequence-speciﬁc DNA ampliﬁcation [25].
The probe used for the ASO reverse primer approach
is normally designed for the V gene segment. It works like
the ASO forward primer but in the opposite orientation.
Here, the reverse primer is positioned at the tumor-speciﬁc
sequence.
The ASO forward primer has advantages over the ASO
reverse primer approach [25]; ﬁrst is the location of the
probe. The ASO forward primer locates to the J segment.
Due to the lower number of J gene segments than V
gene segments, where the ASO reverse primer binds, a
lower number of probes have to be designed for the ASO
forward primer approach than for ASO reverse primers [25].
Furthermore, ASO reverse primers are more prone to target
loss due to VH-replacement and somatic hypermutations,
which are often found in V gene segments [46, 47], although
somatic hypermutations are rare in CLL patients [27]. An
advantage of the ASO reverse primer approach over the
ASO forward primer might be increased sensitivity due to
the higher number of V gene segments. However, no data
supporting this hypothesis have as yet been published [25].
Many studies report that ASO RQ-PCR is the method
with the highest sensitivity for MRD detection in CLL
[7, 10, 24]. B¨ ottcher et al. [24] compared the eﬃciency of
consensus PCR, ASO RQ-PCR, and MRD Flow for detecting
M R Di nC L Lc e l l sa f t e ra l l o g e n e i ca n da u t o l o g o u sS C T .
The ASO primers were designed for the hypervariable N-
D-N region of the IgH-CDR3, the antibody combination
fortheMRDFlowassaycomprisedCD19/CD5/CD20/CD43,
and consensus PCR used an FR1-IgH primer set. From
the 74 patients included in this study, the authors analyzed
92 samples from 40 patients in parallel using ASO RQ-
PCR and MRD Flow. ASO RQ-PCR detected MRD in 61
samples whereas MRD Flow only detected MRD in 47
samples. All MRD Flow+ samples were also ASO RQ PCR+.
Concordant positive results were generated in 51.1% (47
samples) of all samples whereas 33.7% (31 samples) gave
concordant negative results [24]. Thus, the same qualitative
results (MRD
− or MRD+) were reached with 84.8% (78
samples) of all examined samples. The quantitative MRD
levels detected in the 51.1% of concurring positive samples
werewellcorrelated(r = 0.93,P<. 0001)[24]withamedian
level of 3.2×10
−3 forMRD Flow and 6.1×10
−3 for ASO RQ-
PCR [24].
Eight patients (14 samples) were positive for ASO RQ-
PCRbutnegativeforMRDFlow.Thesepatientshadverylow
levels of disease with a median range of 5.2 × 10
−5 (range
1.3 × 10
−5 to 1.6 × 10
−3). In two of these patients, both
methods detected MRD at diﬀerent time points in the study
[24].8 Advances in Hematology
Taken together, they found well-correlated results
between both methods within the guidelines set for sen-
sitivity, which was attained by both techniques. ASO RQ-
PCR could detect lower MRD levels than MRD Flow,
and therefore ASO RQ-PCR is the method of choice for
identifying very low levels of disease. The role of consensus
PCR was again shown to be inferior [24].
Intheabovedescribedstudy[22],whencomparingMRD
Flow and ASO RQ-PCR in rituximab-treated patients, the
ASO RQ-PCR was designed with the speciﬁc ASO primer
matching the hypervariable N-D-N region of the individual
CLL clone, plus conventional reverse and forward primers.
Ampliﬁcation of polyclonal DNA frompooled healthy donor
samples in every PCR cycle was used to calibrate speciﬁcity.
Optimal sensitivity and speciﬁcity were reached by analyzing
diﬀerent temperatures for the annealing step [22]. Again
the results revealed concordant qualitative and quantitative
MRD detection for both methods, and again ASO RQ-PCR
proved to be more sensitive for lower MRD levels up to
10
−5 [10, 24]. The authors attested good speciﬁcity and
quantiﬁcation for both methods in clinical diagnostics, as
long as the recorded results were within the sensitivity and
quantitative ranges, as calculated using serial dilutions.
Rawstron et al. [10] also identiﬁed ASO RQ-PCR as the
method with the highest sensitivity. They compared MRD
Flow and ASO RQ-PCR in 57 samples from 39 patients.
MRD Flow was performed as described above, while ASO
primersweredesignedfortheCDR3regionandtheDNAwas
isolated and ampliﬁed according to the BIOMED-2 protocol
[36]. Serial dilutions were used to create a standard, and
sensitivity and speciﬁcity were deﬁned as the last dilution
w h e r et a r g e tD N Aw a sd e t e c t a b l e[ 10]. The authors showed
that both methods reached equal eﬃcacy for MRD detection
atacutoﬀof0.01%,butASORQ-PCRhadgreatersensitivity
with a limit of MRD detection below 0.001%.
An advantage of ASO RQ-PCR compared to conven-
tional consensus PCR is that speciﬁcally designed oligonu-
cleotides can overcome interference by healthy B cells
that have similar IgH segments [7], explaining the higher
sensitivity of ASO RQ-PCR. However, MRD detection with
ASO RQ-PCR is expensive and time consuming, thus not
available in every diagnostic laboratory.
5. Discussion
If the more potent therapies developed recently to treat
CLL are to achieve their full potential, highly sensitive MRD
detection is essential to obtain prognostic information,
evaluate therapeutic responses, and monitor posttreatment
patients [7, 10, 13, 14]. Rather insensitive and only
qualitative methods such as CD19+/CD5+ ﬂow cytometry
or consensus PCR are no longer suﬃcient for accurately
assessing MRD in CLL [10]. Instead, multiparamer ﬂow
cytometry (MRD Flow) and allele speciﬁc oligonucleotide
immunoglobulin heavy chain real-time quantitative
polymerase chain reaction (ASO IGH RQ-PCR) techniques
have been validated as being not only more sensitive, but
also quantitative by ﬁve extensive studies reviewed here
[7, 10, 15, 22, 24].
To ensure optimal application of these techniques,
a number of working parameters are needed, such as
deﬁning which patient material to use; establishing sen-
sitivity, speciﬁcity, quantiﬁcation ranges, and correlation
with patient prognosis; setting international standards for
comparing results in diﬀerent settings and between meth-
ods; deﬁning ease of application, costs, required exper-
tise, and whether the cytometry assays are functionality
independent of previous therapies, including monoclonal
antibodies.
All the studies directly compared MRD Flow and ASO
RQ-PCR with conventional ﬂow cytometry and PCR,
analyzing peripheral blood and/or bone marrow from
patients following diﬀerent standard treatments, including
rituximab [22], alemtuzumab [7], or allogeneic/autologous
SCT[7,15,24].Previousinvestigatorshadalreadyconﬁrmed
that using the appropriate patient material is critical, since
speciﬁcity may decrease due to the treatment, the sampling
time point, or technical limitations [10]. For prognostic
information, not only the sensitivity of the chosen MRD
detection technique is important but also MRD kinetics
and the patient sample type [15], since CLL disease kinetics
are diﬀerent for peripheral blood and bone marrow [1].
MRD assessment during, or shortly after, administrating
monoclonal antibody regimes optimally requires bone
marrowanalyses[10,23].However,evaluationoftherapeutic
response and prognostic values can also use peripheral blood
without losing speciﬁcity or sensitivity, a signiﬁcant beneﬁt
for patients since blood withdrawal is not as invasive as bone
marrow aspiration.
It is essential to standardize MRD assays to compare
therapeutic treatments and use MRD as a prognostic marker.
In 2007, Rawstron et al. outlined an international standard
approach to ﬂow cytometry analyses [10], that is, in line
with the former international guidelines [8]. This included
proposals for blood processing, antibody combinations,
and gating strategies [10]. Flow cytometry analyses that
can use whole blood and diﬀerent protocols for blood
preparation have been applied although the international
standard recommends preparation with whole blood lysates
to eliminate erythrocytes. Density-gradient centrifugation
should not be used for cell preparation, since quantitative
MDR analyses were inaccurate due to variable cell recovery,
especially in bone marrow [10].
For standardized MRD detection, settings were cho-
sen that are not, or only marginally, inﬂuenced by
the presence or absence of any therapeutic components,
including monoclonal antibodies. Of particular signiﬁcance
was the observation that MRD Flow analyses are unaf-
fected by the presence of monoclonal antibody rituximab
[22].
Together with gating strategies, speciﬁc antibody com-
binations were used in MRD Flow to separate CLL cells
from other PBMC [7, 22]. Previously, high numbers of
healthy cells limited CLL cell detection [44]. With the more
advanced multicolor ﬂow cytometry, it is now possible to
measure large numbers of cells, overcoming the problem of
interference by too many healthy cells, and thus increasing
speciﬁcity.Advances in Hematology 9
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ASO RQ-PCR are able to detect MRD levels within
the international guideline threshold, with high accuracy.
When MRD levels are between 10
−4 and 10
−5 or even
lower, only ASO RQ-PCR can provide qualitative detection,
since it proved to be more sensitive than MRD Flow.
However, both methods gave correlating results, therefore
highlighting the clinical relevance of both MRD Flow and
ASO RQ-PCR.
Higher sensitivity of ASO RQ-PCR is due to the indi-
vidual primer designed for every patient clone. Interference
by other healthy B cells is therefore very low, allowing high
sensitivity even for very low disease levels. The speciﬁcity
depends on the length of the gene segment and the annealing
temperature [22, 25]. Analyzing complete V-D-J rearrange-
ments in the IgH gene showed higher sensitivity than
analyzing the smaller V-J rearrangement segment [25, 48].
However, since speciﬁc primers address only one rearranged
IgH gene sequence, the risk of target gene loss due to
ongoing rearrangements in the IgH region is high and leads
to reduced speciﬁcity. In addition, normal B cells with sim-
ilar VDJ rearrangements can produce false positive results
[25].
Certainlybothtechniqueshaveadvantagesanddisadvan-
tages. Although MRD Flow is available in most laboratories
and is less expensive than ASO RQ-PCR, its sensitivity
is somewhat lower than ASO RQ-PCR, and training and
expertise are important to achieve reliable results. The
sensitivity and speciﬁcity of MRD Flow can be reduced
by some parameters that generate false negative or false
positive results. Using whole blood for MRD Flow analyses,
blood processing or the use of diﬀerent antibodies are highly
relevant for the quality of the results. In general, monoclonal
antibodies are used for MRD detection since it is technically
easier to develop standardized batches of monoclonal rather
than polyclonal antibodies. A major disadvantage of ASO
RQ-PCR the high costs for IgH sequencing although blood
from patients in clinical trials is routinely sequenced to
evaluate IgH mutations or ﬁnd prognostic markers [10].
Also, due to diﬀerences in the quality of DNA samples, it
is necessary to normalize their amount and quality, which
can be performed by using albumin genes, for example, as
internal references [24].
In summary, MRD can be eﬀectively determined in CLL
patients by multiparameter ﬂow cytometry, since within a
sensitivity range of down to 10
−4, it provides information
as accurate as ASO RQ-PCR. However, ASO RQ-PCR
oﬀers even higher qualitative sensitivity, which might be
relevant if the therapeutic aim is complete eradication
of the disease. Since multiparameter ﬂow cytometry is
widely available and no standard treatment can cure CLL,
this technique should be considered a routine method. In
contrast, ASO RQ-PCR analyses should be limited to a few
specialized laboratories that can cope with the necessary
expenditure; presently it is only indicated within clinical
trials. Possibly, new antibody combinations and, most
importantly, very recent technological improvements will
further enhance the sensitivity of ﬂow cytometric analyses
[24].
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